In the past, if the women’s health market hasn’t been a "hot spot" of investing, that’s because successful exits for medtech companies operating in that space have been few and far between. But the times are changing. The 2004 acquisition of start-up Novacept Inc. by Cytyc Corp. for $325 million [See Deal] and now the proposed $6.5 billion merger of Hologic Inc. and Cytyc, two women’s health companies, which even before the merger, had gained critical mass with an acquisition strategy, have drawn attention to the opportunities in women’s health. The Cytyc/Hologic deal would also create a stronger acquirer, one that defines women’s health as broadly encompassing breast cancer, cervical cancer, menorrhagia, osteoporosis, preterm labor, contraception, and endometriosis. [See Deal](See "Cytyc Merges with Hologic," this issue.) Now, a new crop of medtech start-ups stands ready to fill unmet needs in all of these areas, and more.
The ability of imaging technologies to find ever smaller breast tumors is putting current excisional technologies to the test. Surgeons...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
